Comparative confirmatory study of K-877

Phase3 comparative confirmatory study of K-877 against fenofibrate

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222569

Enrollment

225

Registered

2014-07-29

Start date

2014-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Interventions

investigational material(s) Generic name etc : K-877 INN of investigational material : Therapeutic category code : 218 Agents for hyperlipidemias Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients who have been placed on dietary or exercise therapy for 12 weeks or longer prior to the initiation of treatment period (2)men or postmenopausal women (3)20 years or older at the time of informed consent etc

Exclusion criteria

Exclusion criteria: (1)Type 1 diabetes mellitus or poorly controlled Type 2 diabetes mellitus -HbA1c(NGSP): >= 8.0%(at the screening test) (2)Poorly controlled hypertension -SBP: >=160 and/or DBP: >=100 mmHg (at the screening test) (3)Poorly controlled thyroid disorder etc

Design outcomes

Primary

Measure	Time frame
Efficacy: TG Safety: AE and ADR Efficacy: percent change from baseline Safety: incidence rate	—

Secondary

Measure	Time frame
Efficacy: TC, HDL-C etc. Safety: laboratory tests, vital signs and physical examination Efficacy: percent change from baseline Safety: change in the laboratory tests, vital signs and physical examination	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026